Shield Therapeutics (LON:STX) Trading Up 11% - Should You Buy?

Key Points

• Shield Therapeutics shares surged by 11%, reaching a high of GBX 9.40 ($0.13) before settling at GBX 9.10 ($0.12).
• The company has a market cap of £97.35 million and a significant debt-to-equity ratio of 3,691.50.
• Shield Therapeutics specializes in delivering Accrufer®/Feraccru®, an innovative treatment for iron deficiency patients.

Shares of Shield Therapeutics plc (LON:STX - ) shot up 11% on Friday . The company traded as high as GBX 9.40 ($0.13) and last traded at GBX 9.10 ($0.12). 5,965,360 shares changed hands during mid-day trading, an increase of 121% from the average session volume of 2,698,770 shares. The stock had previously closed at GBX 8.20 ($0.11).

Shield Therapeutics Price Performance

The firm's fifty day simple moving average is GBX 5.38 and its two-hundred day simple moving average is GBX 3.63. The firm has a market cap of £97.35 million, a PE ratio of -467.25 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.